{
  "image_filename": "figure_p4_det_3_007.png",
  "image_path": "FlublokPI/extracted/figures/figure_p4_det_3_007.png",
  "image_type": "Figure",
  "page_number": 4,
  "block_id": "det_3_007",
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "supports_claim": false,
  "explanation": "A table comparing attack rates (n/N and %) of PCR-confirmed influenza for recombinant quadrivalent influenza vaccine (RIV4) versus a comparator egg-based quadrivalent vaccine, listing relative risk (RR) and relative vaccine efficacy (rVE % with 95% CI) for different influenza strains does not support the claim: the table shows comparative efficacy data but does not address broader immune response or cross-protection in a mismatch season Note: Table lacks explicit mention of mismatch season or immunologic breadth; context on antigenic drift is not visible",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A table comparing attack rates (n/N and %) of PCR-confirmed influenza for recombinant quadrivalent influenza vaccine (RIV4) versus a comparator egg-based quadrivalent vaccine, listing relative risk (RR) and relative vaccine efficacy (rVE % with 95% CI) for different influenza strains",
    "evidence_found": null,
    "reasoning": "does not support the claim: the table shows comparative efficacy data but does not address broader immune response or cross-protection in a mismatch season",
    "confidence_notes": "Table lacks explicit mention of mismatch season or immunologic breadth; context on antigenic drift is not visible"
  }
}